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Mutations in CCAAT/enhancer binding protein α (CEBPA) occurin 5-10% of cases of acute myeloid leukemia. CEBPA-double-mutated cases usually bear bi-allelic N- and C-terminal muta-
tions and are associated with a favorable clinical outcome. Identification
of CEBPA mutants is challenging because of the variety of mutations,
intrinsic characteristics of the gene and technical issues. Several screening
methods (fragment-length analysis, gene expression array) have been
proposed especially for large-scale clinical use; although efficient, they
are limited by specific concerns. We investigated the phenotypic profile
of blast and maturing bone marrow cell compartments at diagnosis in
251 cases of acute myeloid leukemia. In this cohort, 16 (6.4%) patients
had two CEBPA mutations, whereas ten (4.0%) had a single mutation.
First, we highlighted that the CEBPA-double-mutated subset displays
recurrent phenotypic abnormalities in all cell compartments. By muta-
tional analysis after cell sorting, we demonstrated that this common phe-
notypic signature depends on CEBPA-double-mutated multi-lineage
involvement. From a multi-dimensional study of phenotypic data, we
developed a classifier including ten core and widely available parameters.
The selected markers on blasts (CD34, CD117, CD7, CD15, CD65), neu-
trophil (SSC, CD64), monocytic (CD14, CD64) and erythroid (CD117)
compartments were able to cluster CEBPA-double-mutated cases. In a
validation set of 259 AML cases from three independent centers, our clas-
sifier showed excellent performance with 100% specificity and 100%
sensitivity. We have, therefore, established a reliable screening method,
based upon multi-dimensional analysis of widely available phenotypic
parameters. This method provides early results and is suitable for large-
scale detection of CEBPA-double-mutated status, allowing gene sequenc-
ing to be focused in selected cases.
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ABSTRACT
Introduction 
Mutations in the transcription factor CCAAT/enhancer
binding protein α (CEBPA) are found in approximately
10% of cases of acute myeloid leukemia (AML).1-3 Most
CEBPA-mutant AML exhibit two mutations, which fre-
quently involve a combination of an N-terminal and a C-
terminal gene mutation, typically on different alleles.
Recent comprehensive data have shown that CEBPA-dou-
ble-mutated (CEBPA-dm) cases, rather than single
mutants, are associated with a common gene expression
signature4 and a relatively favorable outcome.4-7 Based on
these features, CEBPA-dm AML has been recognized as a
separate entity in the revised World Health Organization
classification.8 The identification of a CEBPA-dm genotype
provides crucial prognostic information, since these
patients often lack other main predictors of relapse risk.
However, there are several technical issues with CEBPA
mutational analysis. First, CEBPA sequencing is known to
be difficult because of the high GC content of the gene,
which frequently correlates with failure of the polymerase
chain reaction, and the presence of background or
sequencing artifacts. Sequencing the entire gene enables
detection of all mutations but is labor-intensive, especially
in a routine context, and requires expertise with unusual
variants. Several screening methods have, therefore, been
developed. Although efficient and sensitive, polymerase
chain reaction-based fragment-length analyses can only
detect mutations resulting in a net insertion or deletion
and not substitution mutations.9,10 Furthermore, they can-
not distinguish a common 6-bp duplication polymorphism
from an actual insertion or duplication.11 Next-generation
sequencing-based CEBPA studies are able to overcome
these difficulties but are not widely available yet. Some
reports have proposed gene expression arrays as a screen-
ing method for CEBPA-dm status, given the unique profile
of these malignancies.4,6,12-14 Although these methods have
excellent performance, they require further technology
and relative expertise for specific application in this con-
text.
As a screening method for genetic abnormalities, the
immunophenotype of AML blasts is often able to predict
the main underlying genotypes.15 Generally, the associa-
tion with phenotype is strong when a few, relevant genet-
ic events are responsible for leukemogenesis [e.g., CBF-
related translocations or t(15;17)], whereas it is weaker
when genetic heterogeneity is greater (e.g., normal karyo -
type with several gene mutations). Furthermore, the
strength of the correlation with a certain genotype
depends on phenotypic aberrations being rare in AML not
characterized by that genotype [e.g., cross-lineage CD19
and t(8;21)]. In fact, CEBPA-mutated AML has not been
associated with a specific immunophenotype. Rather, it
has been described as showing positivity for commonly
expressed antigens, such as CD15, CD7, CD34 and HLA-
DR on blasts.16 Although associated with a mutant status,
this phenotypic profile was not able to screen effectively
for CEBPA-mutated cases, since about 25% of them were
missed.16 Furthermore, it was based on the strict applica-
tion of the European Group for Immunological
Characterization of Leukemia (EGIL) threshold for positiv-
ity (i.e., more than 20% of cells),17 which is probably inad-
equate for dissecting a shared phenotypic signature, espe-
cially for frequently expressed antigens.
In this study, we extensively investigated the
immunophenotype of CEBPA-mutated AML by analyzing
all bone marrow cell compartments at diagnosis and by
comparing each compartment with its corresponding nor-
mal counterpart in order to highlight aberrations. Our aim
was to develop a screening method for CEBPA-mutated
AML based on the phenotypic profile, which would be
straightforward, widely available and fast, in order to
focus molecular techniques on a narrow subset of AML
patients.
Methods
Patients
Patients entering the study had a diagnosis of untreated AML,
based on World Health Organization criteria.18 and an available
immunophenotypic characterization on bone marrow at diagno-
sis. When eligible for intensive chemotherapy, patients were treat-
ed according to two protocols as specified below. Briefly, from
2006 to March 2007 (protocol 1), patients received standard course
induction. High-dose cytarabine was used as first consolidation in
patients aged <61 years attaining complete remission. On an
intent-to-treat basis, patients aged <55 years with a high-risk
karyo type, FLT3-ITD or adverse clinical features were assigned to
undergo allogeneic stem cell transplantation. Patients with inter-
mediate cytogenetic risk in the absence of FLT3-ITD and adverse
clinical features were allocated to allogeneic stem cell transplanta-
tion if a related donor was available. Autologous stem cell trans-
plantation was offered to patients aged <61 years with low-risk
cytogenetics, intermediate-risk cytogenetics without sibling donor
and high-risk disease not eligible for allogeneic transplantation.
From April 2007 to 2013 (protocol 2), patients were enrolled in the
Northern Italy Leukemia Group (NILG) AML 02-06 protocol
(Eudract code: 2006-003817-42). This protocol included random-
ization at induction between a standard ICE induction and an
experimental, intensified one. Patients randomized to the experi-
mental arm were excluded from the outcome analysis. A more
detailed description of treatment protocols is provided in the
Online Supplementary Data.
Only intensively treated non-M3 patients were considered for
the outcome analysis. The study was approved by the local insti-
tutional review board (protocol number: 2013/0024340), and
patients were included after giving written informed consent, in
accordance with the Declaration of Helsinki.
Karyotype
Cytogenetic analysis was performed on bone marrow cells
taken at diagnosis and the results are reported according to the
International System for Human Cytogenetic Nomenclature.19
Molecular genetics
NPM1, FLT3-ITD and CEBPA mutations were searched for
using previously described methods.1,21,22 Further details are report-
ed in the Online Supplementary Data.
Flow cytometry
Technical details about flow cytometry sample handling,
reagents, acquisition and analysis are reported in the Online
Supplementary File. Data were analyzed with Infinicyt software
(Cytognos SL, Salamanca, Spain). Some major bone marrow cell
compartments were identified: (i) blasts; (ii) maturing neutrophils;
(iii) monocytes; and (iv) mature erythroid cells. A series of 79 phe-
notypic parameters were defined (24 for blasts, 30 for the neu-
trophils, 14 for the monocytic compartment and 11 for erythroid
cells). Parameters were expressed as percentage of positive cells for
F. Mannelli et al.
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an antigen and/or as mean fluorescence intensity (MFI; arbitrary
relative linear units, scaled from 0 to 104). Bone marrow samples
from 21 healthy donors (male 13, female 8; median age 36 years;
range, 20-59)  were used to define the normal phenotypic profile
(mean value ± two standard deviations for each parameter).
CEBPA mutation analysis on sorted cells
Cell sorting was performed using a FACSAria flow cytometer
(BD) on diagnostic fresh bone marrow samples from six patients
with CEBPA-dm AML. Some customized tubes were designed
based on the phenotypic profile at diagnosis in order to sort spe-
cific cell fractions: (i) blasts; (ii) monocytes; (iii) maturing neu-
trophils; (iv) erythroid lineage cells; and (v) T-lymphocytes. Purity
checks were performed to ensure sorting quality. Dead cells were
excluded by analyzing forward scatter (FSC) versus side scatter
(SSC) dot plots. Doublets were excluded by a FSC-height versus
FSC-area dot plot. CEBPA mutational analysis was carried out on
sorted cell fractions to reveal clonal multi-lineage involvement.
Statistical analysis
Data were processed using R software (http://cran.r-
project.org). Comparisons between groups were performed using
the Mann–Whitney U test. P values <0.05 were considered to
denote statistically significant differences. Complete remission
was defined using established criteria.23 Principal component
analysis was used to visualize the similarity of phenotypic pro-
files, comparing CEBPA-dm cases with other genotypes. We per-
formed Ward hierarchical clustering to reveal recurrent pheno-
typic aberrations and used Euclidean distance as the distance
measure on phenotypic parameters. Consistent with the cluster-
ing strategy, we developed a Euclidean distance-based classifier
on a selected group of phenotypic parameters to predict CEBPA-
dm status. Samples in the validation dataset showing a distance
between their normalized phenotypic data and the CEBPA-dm
reference vector less than or equal to a classification threshold
were considered “highly probable” cases of CEBPA-dm. In order
to allow the method to be reproduced, the R script to perform the
prediction of CEBPA-dm status is available in the Online
Supplementary Data.
Results
Characterization of patients according to CEBPA
genotype
Between 2006 and 2013, 318 consecutive patients were
diagnosed with AML at our Institution. Enrollment criteria
for the present study were the availability of: (i) a full
immunophenotype (i.e., including all required phenotypic
parameters) on bone marrow at diagnosis; (ii) karyotype;
and (iii) molecular genetics for NPM1, FLT3 and CEBPA.
On the basis of these criteria, 67 patients were excluded
because of incomplete immunophenotype on bone mar-
row (n=32), immunophenotype on peripheral blood
(n=23), and lack of molecular genetics and unavailability
of a diagnostic cryopreserved specimen (n=12). Thus, 251
patients met all criteria and were studied. Their character-
istics are summarized in Table 1. In this cohort, 42 CEBPA
mutations were identified in 26 patients (10.3%). Sixteen
CEBPA-double-mutated AML has a unique phenotype
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Table 1. Characteristics of patients according to CEBPA status.
Characteristics Total CEBPA-wt CEBPA-sm CEBPA-dm P P
(n=251) (n=225, 89.6%) (n=10, 4.0%) (n=16, 6.4%) (wt vs. dm) (wt vs. sm)
Age, median (range), years 57 (16-81) 57 (16-81) 60.5 (31-69) 48.5 (23-72) 0.0434 0.77
Diagnosis
de novo 228 (91.9%) 203 (91.2%) 9 (90.0%) 16 (100.0%) - 1.0
secondary 23 (9.1%) 22 (9.8%) 1 (10.0%) -
WBC, x109/L 16.9 (0.5-435.0) 16.5 (0.6-415.0) 57.1 (13.1-435.0) 8.1 (1.2-166.0) 0.54 0.007
Hb, g/dL 9.0 (3.9-14.9) 8.9 (3.9-14.9) 9.5 (7.0-10.8) 10.6 (4.1-13.4) 0.004 0.8219
Reticulocytes, 0.77 (0.029) 0.57 (0.022) 0.32 (0.011) 2.355 (0.098) <0.0001 (0.16) 0.086 (0.09)
median % (abs, 1012/L)
Platelets, x109/L 43 (3-815) 45 (3-815) 54 (7-99) 24 (10-193) 0.025 0.6455
BM blasts, % 90 (15-100) 90 (15-100) 92 (40-100) 80 (40-100) 0.4575 0.4388
Cytogenetics
t(15;17) 18 (7.2%) 18 (8.0%) - - - -
favorable 37 (14.7%) 37 (16.4%) - - - -
normal karyotype 119 (47.4%) 97 (43.1%) 9 (90.0%) 13 (81.3%) 0.0037 0.006
other intermediate 29 (11.6%) 28 (8.0%) - 1 (6.2%) 1.0 -
adverse 38 (15.1%) 38 (16.9%) - - - -
lack of growth 8 (3.2%) 5 (2.2%) 1 (10.0%) 2 (12.5%) 0.31 0.51
not available 2 (0.8%) 2 (0.9%) - - - -
NPM1
mutated 67 (26.7%) 59 (26.2%) 8 (80.0%) - - 0.0008
wild-type 184 (73.3%) 166 (73.8%) 2 (20.0%)
FLT3
ITD 50 (19.9%) 47 (20.9%) 3 (30.0%) - - 0.28
D835 PM 6 (2.4%) 5 (2.2%) 1 (10.0%) - -
wild-type 195 (77.7%) 173 (76.9%) 6 (60.0%) 16 (100.0%) -
WBC: white blood cells; Hb: hemoglobin; abs: absolute count; BM: bone marrow; ITD: internal tandem duplication; PM: point mutation. Lack of growth means no metaphases.
out of the 26 patients (61.5%) had two CEBPAmutations,
whereas the remaining ten (38.5%) had a single mutation.
The 16 patients with two CEBPA mutations had both an
N-terminal truncation mutation resulting in p30 CEBPA
and a C-terminal mutation affecting the bZIP domain of
CEBPA. A summary of detected mutations is reported in
Table 2. According to the number of mutations in the
CEBPA gene, we divided our cases into: patients with dou-
ble N- and C-terminal CEBPA mutations (CEBPA-dm,
n=16), patients with a single mutation (CEBPA-sm, n=10),
and wild-type patients without any mutation (CEBPA-wt,
n=225). As regards clinical and biological features at diag-
nosis, CEBPA-dm patients were younger, had higher
hemoglobin values and reticulocyte percentages and
lower platelet counts compared to CEBPA-wt subjects.
Consistently with published literature,7 a higher incidence
of normal karyotype and no mutations of NPM1 and FLT3
genes were observed in CEBPA-dm cases. CEBPA-sm
patients had higher white blood cell counts, as well as
higher incidences of normal karyotype and NPM1 muta-
tions with respect to CEBPA-wt cases.
Clinical outcome
Two-hundred and two patients out of 251 had non-M3
AML and were intensively treated. In accordance with
previous studies,5-7 CEBPA-dm patients, compared to
CEBPA-wt patients, showed a trend toward a higher com-
plete remission rate after the first cycle of treatment
(87.5% versus 61.0%, respectively; P=0.0549), longer over-
all survival (median not reached versus 22.3 months,
respectively; P=0.00626; Figure 1A) and longer disease-
free survival (median not reached versus 26.8 months,
respectively; P=0.0667; Figure 1B). These findings did not
change significantly when patients undergoing allogeneic
stem cell transplantation were censored at the time of
their transplant (Figure 1C,D).
Table 2. Summary of CEBPA mutations in the primary cohort.
N., sm/dm Mutation 1 – position in CDS Mutation 1- Mutation 2 – Mutation 2 – 
position in protein position in CDS position in protein
N-term, nt-29_518 Middle, C-term, AA consequence C-term, AA consequence
nt-469_858 nt-816_1171 nt-816_1171
1, sm c.62_63dupAG p.S21Rfs*160
2, dm c.62_63dupAG p.S21Rfs*160 c.929_930insAAG p.T310_Q311insR
3, sm c.247delC p.Q83Sfs*159
4, sm c.933_934insCGG p.Q311_Q312insR
5, sm c.609_610insGCACCTG P.Q207Afs*322
6, sm c.68dupC p.H24Afs*74
7, dm c.180_186delGTCCATC p.S61Tfs*157 c.913_950dup P.305_317dupQRNVETQQ
KVLEL
8, sm c.196_199dupGCCT p.Y67fs*107
9, sm c.888G>A p.V296=
10, dm c.97_112delTTTCCCCGGGGCGCGG p.F33Afs*154 c.992T>C p.L331P
11, dm c.146delC p.P49Rfs*159 c.937_939dupAAG p.K313dup
12, dm c.65_103del (-43bp) p.H24Rfs*143 c.919_954dup (+36bp) p. N307_T318dup (+12AA)
13, dm c.247delC p.Q83Sfs*159 c.916_945dup (+30bp) p.R306_L315dup (+10AA)
14, dm c.198_201dupCTAC p.I68Lfs*41 c.929_930delCGins p.E309_Q311delinsRHHTSQ
GGCACCACACCTCTCAA
15, dm c.247delC p.Q83Sfs*159 c.937_939dupAAG p.K313dup
16, dm c.291delC p.T98Rfs*159 c.928_929insAGTCTA p.E309_T310insKS
17, dm c.178_188delACGTCCATCGA (-11bp) p.T60Hfs*103 c.901_924dup p.D301_V308dup
18, sm c.209_210insC p.A71Gfs*107
19, dm c.338_339insCCGG p.G114fs*170 c.937_939dupAAG p.K313dup
20, dm c.62_63dupAG p.S21Rfs*160 c.937_939dupAAG p.K313dup
21, dm c.247delC p.Q83Sfs*159 c.930_931insCAC p.T310_Q311insH
22, dm c.318_319dupTG p.D107Vfs*54 c.1066_1071delAACTGC p.N356_C357del
23, dm C.217_218insC p.F73Sfs*35 c.1053_1054ins129 p.V351_352ins43
24, dm c.144_154del11 p.P49fs*55 c.1065_1066insGCC p.G355_N356insA
25, sm c.148G>T p.E50Ter
26, sm c.1009A>T p.T337S
AA: amino acid number; CDS: coding DNA sequence; ins: insertion; del: deletion; dup: duplication, nt: nucleotide. Nucleotides numbered from the major translational start codon at nucleotide
position mutated. NCBI Reference Sequence is NM_004364.4. The description of sequence variants is according to the nomenclature of the HVGS site.
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CEBPA status and immunophenotypic findings
We quantified bone marrow cell compartments at diag-
nosis and found that their distribution varied widely
among patients. The blast compartment represented a
median of 45.49% (range, 0.14-97.74) of the global cellu-
larity, the monocytic compartment 5.53% (range, 0.00-
90.32) and the neutrophil and erythroid series accounted
for 9.29% (range, 0.03-71.76) and 2.32% (range, 0.0-
55.96), respectively. Phenotypic parameters were evaluat-
ed and compared among CEBPA genotypic groups and
also to the cell counterpart in a control group, in order to
highlight deviations from the normal phenotypic profile
(Online Supplementary Data - Online Supplementary Tables
S1-S4). CEBPA-dm cases showed some recurrent abnor-
malities in blasts and also in major maturing cell compart-
ments in the bone marrow. With respect to control CD34+
cells, blasts from CEBPA-dm patients displayed high and
homogeneous expression of immature antigens (CD34,
CD117, HLA-DR) with asynchronous maturation (con-
comitant high expression of CD15, CD65, CD64, cyMPO)
and aberrant cross-lineage expression of CD7. Beyond
being merely defined as CD7+, CEBPA-dm cases showed a
peculiar CD7 expression, since the vast majority of blasts
expressed this antigen (Figure 2B). Similar findings were
observed for antigens of maturation such as CD15 and
CD65 (Figure 2C and Online Supplementary Figure S2). The
median level of expression for these antigens was also sig-
nificantly higher than observed in CEBPA-wt AML (Online
Supplementary Table S1). Five out of 16 (31.3%) CEBPA-dm
cases displayed cross-lineage CD56 expression on blasts.
CEBPA-sm cases showed more heterogeneous phenotypic
patterns (Figure 2 and Online Supplementary Figure S2).
CEBPA-dm AML displayed several recurrent phenotypic
abnormalities in the maturing cell compartment as well.
The most frequently observed abnormalities in the neu-
trophil compartment were low SSC (35.3% of cases;
Figure 2D), lower expression of CD65 and higher expres-
sion of CD64 compared both to controls and CEBPA-wt
and –sm cases (Online Supplementary Figure S3). Monocytic
cells, although not quantitatively expanded compared to
controls (mean percentage 2.6% versus 4.6%), were recur-
rently characterized by high expression of CD64 (Figure
2E) and low expression of CD36 (Online Supplementary
Figure S4). The erythroid compartment was significantly
more represented in CEBPA-dm cases (7.2%) than in
CEBPA-wt (1.6%) and CEBPA–sm (0.7%) cases, being sim-
ilar to control values (8.9%). Furthermore, CEBPA-dm
cases shared a significant increase of more immature
stages of erythroid series, as revealed by high expression
of CD117 (Figure 2F) and CD105, and some antigenic
CEBPA-double-mutated AML has a unique phenotype
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Figure 1. Survival outcomes according to CEBPA gene status. An outcome analysis was carried out for the 202 of 251 patients who were intensively treated. Kaplan
Meier curves are stratified on CEBPA status: CEBPA-wild type (blue), single mutants (green), and double mutants (red) with P values representing the comparison
versus wild-type patients. (A) Disease-free survival; (B) overall survival; (C) disease-free survival and (D) overall survival after censoring allo-transplanted patients at
the date of transplant.
A B
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abnormalities (low CD36, low CD71) (Online
Supplementary Figure S5).
CEBPA-double-mutated status and multi-lineage
involvement
As previously reported, CEBPA-dm AML is often char-
acterized as M1-M2 according to the French-American-
British classification.24 Available published data show that
about 20-25% of CEBPA-dm cases are associated with
multi-lineage dysplasia, as defined by the World Health
Organization (i.e. presence of >50% of dysplastic cells in
at least 2 cell lineages).18 In our series, five out of 16
(31.3%) CEBPA-dm cases showed multi-lineage dysplasia
by morphology. Specifically, erythroid dysplasia was
observed in the majority of patients (10 out of 16, 62.5%),
which is relatively higher than expected for a de novo,
intermediate karyotype category. In this respect, the mor-
phological findings are consistent with phenotypic data:
as reported above, maturing cell compartments, and espe-
cially the erythroid one, showed aberrant phenotypic pat-
terns that were recurrent in this genotypic subset. We thus
investigated whether CEBPAmutations were clonally rep-
resented in maturing cell lineages. In order to do this, we
performed CEBPA mutational status analysis after separa-
tion by fluorescence-activated cell sorting in six out of 16
CEBPA-dm patients from our cohort. Overall, post-sorting
acquisition of isolated cell fractions documented a purity
of 97±1%. We were able to isolate blast, neutrophil,
monocytic and erythroid cell compartments from all six
patients; T-lymphocytes were employed as a negative
control. In addition to blast cells, all sorted myeloid popu-
lations showed a CEBPA-dm status, whereas T lympho-
cytes were CEBPA-wt. The data from one illustrative case
are shown in Figure 3.
Multidimensional analysis and classifier definition
Although recurrent in CEBPA-dm cases, most phenotyp-
ic abnormalities showed a variable degree of overlap with
the distribution of values observed in CEBPA-wt and
CEBPA–sm patients. Consequently, the expression of no
single antigen was able to discriminate CEBPA genotype.
We, therefore, processed our data by multidimensional
analysis in order to verify the capability of the whole phe-
notypic profile, including blasts and more mature com-
partments, to separate the genotypic groups. First we used
principal component analysis to compare CEBPA-dm
cases to some genotypic subsets one by one (Figure 4).
With this method we observed a clear distinction of
CEBPA-dm cases from cases bearing AML1-ETO, CBFB-
MYH11, and NPM1 mutations and a complex karyotype.
A partial overlap emerged for CEBPA-sm cases, essentially
due to one case (Figure 4E) resembling a CEBPA-dm phe-
notype, which had a normal karyotype and was NPM1-
wt and FLT3-wt; neither homozygosity nor a second
CEBPA mutation was identified after gene re-sequencing
on sorted blasts (Online Supplementary Figure S6). No more
sample was available for additional analyses (e.g., next-
generation sequencing).
F. Mannelli et al.
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Figure 2. Phenotypic profile of blasts according to CEBPA status. Box plots illustrate the distribution of values in CEBPA-dm, -sm, -wt and controls for some core
parameters: percentages of (A) CD34, (B) CD15 and (C) CD7 in blasts; (D) SSC signal in neutrophil compartment; (E) CD64 MFI in the monocyte compartment; (F)
CD117 in the erythroid compartment. Box plots were generated by R software. Boxes represent the interquartile range containing 50% of the cases; the horizontal
line marks the median; dots are single cases.
A B C
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Figure 3. CEBPAmutational analysis on sorted cell fractions in one CEBPA-double-mutated patient.  Cell compartments are shown on the left, with core phenotypic
parameters for (A) blasts, (B) neutrophils, (C) monocytes, (D) erythroid cells, and (E) T-lymphocytes. In the corresponding plots, ungated cells are in gray whereas the
relevant cell population is highlighted by color: red for blasts, purple for neutrophils, blue for monocytes, green for erythroid cells and orange for T-lymphocytes. The
relative data from CEBPA mutational analysis are reported on the right, together with mutation type.
A
B
C
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We then carried out an unsupervised clustering analysis
(Figure 5). This approach was able to collect CEBPA-dm
cases into a well-separated cluster. CEBPA-sm cases did
not group separately, probably due to the influence on
phenotype of other relevant gene mutations (e.g., NPM1).
We also carried out hierarchical clustering within selected
subsets, such as the intermediate-risk karyotype category
(Online Supplementary Figure S7). Since CEBPA-mutated
AML has been associated with EGIL-based positivity for
CD7 on blasts,17 we repeated our analysis within CD7+
cases in our cohort (Online Supplementary Figure S8). Our
systematic approach provided clustering of CEBPA-dm
patients even in these subgroup analyses. Given the aver-
age poor prognostic significance of CD7 expression in
AML, we studied outcome in CD7+ cases (Online
Supplementary Figure S9): CEBPA-dm was confirmed to
have a favorable impact in this phenotypic context.
To gain insight into potential influences of additional
genetic changes on phenotype, we studied 12 (out of 16)
CEBPA-dm cases for mutations of TET2 and GATA2 genes,
which are known to be enriched in this subset (Online
Supplementary Table S5). The presence of a mutated status
did not influence clustering in the whole cohort nor within
the CEBPA-dm group (data not shown). 
In order to define a suitable classifier we carried out a
selection of parameters from the initial group of 79.
Selection criteria were first based on coupled comparisons
of single phenotypic parameters among CEBPA-dm versus
F. Mannelli et al.
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Figure 4. Principal component
analysis of CEBPA-dm cases ver-
sus other genotypes. The multi-
dimensional analysis of the
whole phenotypic profile was
able to distinguish CEBPA-dm
cases from other genotypic
groups: AML bearing (A) AML1-
ETO, (B) CBFB-MYH11, (D) NPM1
mutations, (E) complex kary-
otype. (C) CEBPA-single mutant
cases show a wide distribution in
the plot area and a partial over-
lap essentially due to a case
(arrow) resembling a CEBPA-dm
phenotypic profile. Bi-plots are
generated by the combination of
the first two principal compo-
nents (PC), featured by the high-
est values of variance. Ellipses
graphically represent the area of
the 95% confidence interval of
the distribution for the principal
components. Samples outside
the ellipse are outliers. Principal
component analysis was carried
out by R software.
A B
DC
E F
CEBPA-wt, CEBPA-sm or controls. We then selected and
tested several restricted groups of parameters in principal
component analysis and hierarchical clustering. Finally,
we chose one set of ten parameters (Table 3) that pre-
served the ability to separate CEBPA-dm cases in principal
component analysis (Online Supplementary Figure S10) and
clustering analysis (Online Supplementary Figure S11). The
selected markers were: CD34, CD117, CD7, CD15, CD65
on blasts; SSC, CD64 on cells of the neutrophil compart-
ment; CD14, CD64 on the monocytic compartment and
CD117 on erythroid cells. Furthermore, we studied the
efficacy of the parameter set at clustering in a group of
AML samples (n=94), with data also acquired by a
FACSCanto II flow cytometer (Online Supplementary Figure
S12) in order to prove that the method was not affected by
the instrument type. This classifier was thus tested as a
potential screening method for CEBPA-dm genotype in
AML.
Validation of the classifier on an independent cohort
In order to validate the classifier prospectively, we used
a large independent cohort (n=259) of unselected AML
cases from three centers (Bergamo, Brescia and Venice).
FCS files, blinded as regards clinical and biological fea-
tures, were sent electronically to the coordinating center.
The files were then analyzed and parameters tabulated. A
group of controls (n=21) from both centers was analyzed
in parallel to provide a homogeneous reference frame. The
SSC signal of neutrophils was normalized on lymphocyte
SSC. Applying our Euclidean distance-based classifier, a
CEBPA-double-mutated AML has a unique phenotype
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Figure 5. Unsupervised hierarchical clustering according to genotypic groups. Cluster analysis of controls (n=21) and AML cases (n=251) based on the phenotypic
parameters of all bone marrow cell compartments at diagnosis. The CEBPA-double-mutated subset clearly grouped in a separate cluster (dark green in the upper
bar). CEBPA-single mutated cases displayed a heterogeneous distribution (light green in the upper bar). Columns represent individual bone marrow samples; rows
represent the normalized log2 ratios of each parameter analyzed in a given cell compartment divided by the mean value obtained for that parameter in all control
samples. The value of each parameter is represented in a color code according to control values: blue represents expression greater than the mean, red represents
expression lower than the mean, white when not available; color intensity represents the magnitude of the deviation from the mean. Cluster analysis was carried out
using R software.
score was attributed to each case of the validation cohort
(Online Supplementary Table S6). Below a defined thresh-
old, 12 AML cases were considered as “highly probable”
CEBPA-dm. Twelve out of the 12 turned out to bear dou-
ble CEBPA mutations. Of note, no CEBPA-dm cases were
missed by the classifier (i.e., there were no false nega-
tives). Ten out of the 12 CEBPA-dm cases had a combina-
tion of N- and C-terminal mutations. The remaining two
cases showed different mutation patterns: one had one N-
terminal mutation and a nonsense mutation (c.569C>A) in
the middle of the coding sequence; the other had two bi-
allelic C-terminal mutations confirmed by next-generation
sequencing (Online Supplementary File – Online
Supplementary Table S7). The validation set included six
CEBPA-sm cases, which were not highlighted by the clas-
sifier. Considering CEBPA-dm genotype as the target, the
sensitivity and specificity of the classifier were both
100%, as were the positive and negative predictive values
(Table 3). Our classifier was thus validated as a reliable
screening method for CEBPA-dm status on an independ-
ent cohort of AML cases.
Discussion
The identification of CEBPA-dm status in AML has
major clinical importance, allowing relapse risk to be strat-
ified properly for post-remission treatment. However,
most molecular screening methods for its detection have a
number of technical problems. In our study, we developed
an immunophenotype-based screening approach.
Through an extensive phenotypic analysis of a cohort of
251 AML cases, we found that several phenotypic aberra-
tions occurred recurrently on blasts and on maturing cell
compartments in the subset of CEBPA-dm cases. Blasts
showed features of maturation asynchrony with expres-
sion of CD34 and CD117 concomitant with high-intensity
CD15, CD65 and MPO. Further, there was cross-lineage
expression of CD7 by the whole blast cell population
(Figure 1B). This finding is consistent with previous
reports correlating the expression of CD7 in AML to loss
of wild-type CEBPA due to mutations4,16 or silencing by
epigenetic mechanisms.26-28 The neutrophil compartment
showed reduced SSC signals and overexpression of CD64,
with the latter also being seen in monocytes. The ery-
throid series was quantitatively expanded in CEBPA-dm
cases in comparison to both CEBPA-wt and CEBPA-sm
cases, especially at its more immature stages. In fact, the
lack of normal CEBPA function has been associated with
an imbalance of the transcriptional program of
hematopoietic cells, highlighted by the gene expression
profile (upregulation of genes involved in erythroid differ-
entiation, downregulation of HOX gene members),29-31 by
microRNA (over-expression of the miR-181 family)31 and
long non-coding RNA (induction of UCA1 lncRNA)32 sig-
natures. The functional consequences of CEBPA disrup-
tion would thus lead to a block in granulocytic differenti-
ation and a preferential redirection toward the erythroid
lineage.31 This is consistent with the frequent observation
of erythroid dysplasia in CEBPA-dm patients in a previous
study25 and in our cohort. To get insight into these data,
we documented a CEBPA-dm status in all sorted myeloid
cell compartments in six CEBPA-dm AML cases (Figure 3).
Our findings are a proof-of-principle of the correlation
between phenotypic abnormalities and CEBPA-dm status,
indicating the multi-lineage involvement and thus com-
mon clonal origin of different lineages. Moreover these
data account for the observed phenotypic homogeneity,
due to “CEBPA-mutated dependent” pathways of matura-
tion.
The multidimensional analysis of the entire phenotypic
profile was able to separate CEBPA-dm cases efficiently
from all the other genotypes. These results are coherent
with reported gene expression profile data4,6,13 and the
common phenotypic signature further confirms that
CEBPA-dm represents a distinct AML subset. From the ini-
tial list of 79 parameters, we built a classifier from a core
group of ten parameters (Table 3), strictly required by
basic AML diagnostic recommendations.20 We then
applied this classifier to an independent validation set of
AML cases (n=259) from three other centers. Our classifier
performed extremely well (Table 3) in terms of sensitivity
and specificity (100%), and no CEBPA-dm cases were
missed. This is probably the most important feature such
a screening technique should have in order to avoid
overtreatment (i.e. allogeneic transplantation) of patients
with a favorable outcome with chemotherapy. The con-
comitant presence of an FLT3-ITD mutation in one patient
in the validation dataset did not affect its correct classifica-
tion as CEBPA-dm. The profile of one CEBPA-sm case in
the primary cohort overlapped that of the CEBPA-dm
group in principal component analysis. Interestingly, this
case had a normal karyotype and no NPM1 or FLT3muta-
tions, suggesting that in this genetic context, a single
mutation might affect the immunophenotype similarly to
CEBPA-dm status. It is worth noting that the application
of the classifier was not impaired by intrinsic interlabora-
tory variability or by the use of different instruments, sug-
gesting high reproducibility besides stringent standardiza-
tion of the method.
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Table 3. Parameters of the classifier according to cell compartment and performance in the validation cohort as far as concerns prediction of a
CEBPA-double-mutated status.
Cell compartment
Blasts CD34%, CD117 MFI, CD7%, CD15%, CD65%
Neutrophils SSC, CD64 MFI
Monocytes CD14%, CD64 MFI
Erythroid cells CD117%
95% CI 95% CI 
Performance n TP FN TN FP Sensitivity LL UL Specificity LL UL
259 12 0 247 0 100% 100 100 100% 100 100
TP: true positive; FN: false negative; TN: true negative; FP: false positive; CI: confidence interval; LL: lower level; UL: upper level. 
Beyond being technically challenging, interpretation of
the CEBPA mutation pattern can sometimes be debatable
and still crucial in individual cases in terms of prognosis.
The study of functional consequences of CEBPA muta-
tions suggests that the key point of convergence is the
exclusive formation of p30/p30 homodimers.33 This sce-
nario is supposed to be shared by bi-allelic N-terminal and
C-terminal mutations, as well as by the rarer combina-
tions of two N-terminal mutations or an N-terminal
mutation with a frameshift/nonsense mutation in the cen-
tral part of CEBPA.33 One case from the validation set dis-
played the latter pattern and one showed an even rarer7
combination of two C-terminal bi-allelic mutations. Of
note, both of these cases clustered together with the other
CEBPA-dm cases (Online Supplementary File – Online
Supplementary Table S7). The phenotypic profile might be
useful to suspect bi-allelic mutations occurring on the
same gene region, because of the difficult interpretation of
Sanger sequencing in such a context. In contrast, it has
been reported that about 10% of non-homozygous
CEBPA-dm cases carry gene mutations in two different
subclones, an event of uncertain significance for leukemo-
genesis and prognosis.12 Our data suggest that the pheno-
type-based classifier might pick up a shared phenotypic
signature downstream to several mutation patterns, all
leading to a peculiar functional CEBPA disruption, inde-
pendently of mutation type. It could, therefore, enable this
“classical” mutation pattern to be distinguished from alter-
native combinations of gene lesions. We have thus drawn
a workflow embedding the classifier in the diagnostic
work-up of AML (Online Supplementary Figure S13). This
would provide insight into CEBPA-related leukemogenesis
and obviously translate into quickly available prognostic
information.
Being based on phenotypic data, our approach provides
very early results and this goes beyond the mere speeding
up of a focused molecular study. Although it is well-recog-
nized that main genetic prognostic factors drive only the
post-complete remission phase, knowledge about them
since the outset is often meaningful for the clinical man-
agement of patients with AML.
In conclusion, we established a reliable and straightfor-
ward screening method, based simply on the multi-
dimensional analysis of widely available phenotypic
parameters, suitable for large-scale detection of CEBPA-
dm status and potentially able to overcome technical
issues related to molecular methods. Our approach pro-
vides very early results, allowing entire CEBPA sequencing
to be performed in only selected cases. The method has
high specificity and sensitivity, as demonstrated in an
independent AML cohort. This is of major clinical signifi-
cance, since CEBPA-dm patients show a favorable progno-
sis, and knowledge about the CEBPA genotype status per-
mits the use of proportional treatment modalities.
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